Yasuyuki Kobayashi1, Hitomi Kobayashi2,3, Jon T Giles4, Masaharu Hirano5, Yasuo Nakajima1, Masami Takei2. 1. Department of Radiology, St. Marianna University School of Medicine, Kawasaki, Japan. 2. Divisions of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo, Japan. 3. Division of Rheumatology, Itabashi Chuo Medical Center, Tokyo, Japan. 4. Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York City, New York, USA. 5. Division of Cardiology, Tokyo Medical Collage, Tokyo, Japan.
Abstract
OBJECTIVE: The goal of this study was to determine whether the powerful anti-inflammatory effect of anti-interleukin-6 with tocilizumab (TCZ) might lead to a reduction in left ventricular (LV) dysfunction in patients with rheumatoid arthritis (RA). METHODS: Consecutive RA patients with active disease and healthy control subjects without a clinical diagnosis of cardiovascular disease were enrolled. The RA patients each had inadequate clinical response to non-biologic disease-modifying anti-rheumatic drugs and were prescribed TCZ therapy. All subjects underwent baseline evaluation of LV function, as measured by cardiac magnetic resonance imaging (CMRI). Peak systolic regional radial strain (Err, %) was calculated by feature tracking of cine CMRI. After baseline (BL) CMRI measurements, treatment with TCZ was initiated, and patients were followed for 52 weeks. We compared peak Err of RA patients at BL and at 52 weeks. RESULTS: Thirteen RA patients (mean age 52.6 ± 5.4 years) were assessed at BL and at 52 weeks, and these patients were compared with 10 non-RA controls (mean age 55.7 ± 4.6 years). Disease Activity Score of 28 joints - erythrocyte sedimentation rate and Simple Disease Activity Index were significantly lower in RA patients at 52 weeks than at BL. Mean peak Err at BL in RA patients was significantly lower than in normal subjects (P = 0.03). Mean peak Err was significantly higher at 52 weeks than at BL (P = 0.028) in RA patients. CONCLUSION: We showed that TCZ was associated with left ventricular dysfunction in RA patients which correlated with a reduction in RA disease activity.
OBJECTIVE: The goal of this study was to determine whether the powerful anti-inflammatory effect of anti-interleukin-6 with tocilizumab (TCZ) might lead to a reduction in left ventricular (LV) dysfunction in patients with rheumatoid arthritis (RA). METHODS: Consecutive RApatients with active disease and healthy control subjects without a clinical diagnosis of cardiovascular disease were enrolled. The RApatients each had inadequate clinical response to non-biologic disease-modifying anti-rheumatic drugs and were prescribed TCZ therapy. All subjects underwent baseline evaluation of LV function, as measured by cardiac magnetic resonance imaging (CMRI). Peak systolic regional radial strain (Err, %) was calculated by feature tracking of cine CMRI. After baseline (BL) CMRI measurements, treatment with TCZ was initiated, and patients were followed for 52 weeks. We compared peak Err of RApatients at BL and at 52 weeks. RESULTS: Thirteen RApatients (mean age 52.6 ± 5.4 years) were assessed at BL and at 52 weeks, and these patients were compared with 10 non-RA controls (mean age 55.7 ± 4.6 years). Disease Activity Score of 28 joints - erythrocyte sedimentation rate and Simple Disease Activity Index were significantly lower in RApatients at 52 weeks than at BL. Mean peak Err at BL in RApatients was significantly lower than in normal subjects (P = 0.03). Mean peak Err was significantly higher at 52 weeks than at BL (P = 0.028) in RApatients. CONCLUSION: We showed that TCZ was associated with left ventricular dysfunction in RApatients which correlated with a reduction in RA disease activity.
Authors: Sophie I Mavrogeni; Petros P Sfikakis; Theodoros Dimitroulas; Loukia Koutsogeorgopoulou; Gikas Katsifis; George Markousis-Mavrogenis; Genovefa Kolovou; George D Kitas Journal: Rheumatol Int Date: 2018-03-07 Impact factor: 2.631
Authors: Karen G Ordovas; Lauren A Baldassarre; Chiara Bucciarelli-Ducci; James Carr; Juliano Lara Fernandes; Vanessa M Ferreira; Luba Frank; Sophie Mavrogeni; Ntobeko Ntusi; Ellen Ostenfeld; Purvi Parwani; Alessia Pepe; Subha V Raman; Hajime Sakuma; Jeanette Schulz-Menger; Lilia M Sierra-Galan; Anne Marie Valente; Monvadi B Srichai Journal: J Cardiovasc Magn Reson Date: 2021-05-10 Impact factor: 5.364
Authors: Benjamin Castagné; Marie Viprey; Julie Martin; Anne-Marie Schott; Michel Cucherat; Martin Soubrier Journal: PLoS One Date: 2019-08-01 Impact factor: 3.240